Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

First-line Combination Treatment Based on Anlotinib

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03628521
Recruitment Status : Recruiting
First Posted : August 14, 2018
Last Update Posted : August 14, 2018
Sponsor:
Information provided by (Responsible Party):
Baohui Han, Shanghai Chest Hospital

Brief Summary:
The aim of this study is to explore safety and therapeutic efficacy of anlotinib combined with erlotinib/chemotherapy/IBI308 as first-line treatment in advanced NSCLC patients. The primary endpoints of the study are safety and objective response rate (ORR);the secondary endpoints are disease control rate (DCR), progression-free survival (PFS) and overall survival (OS).

Condition or disease Intervention/treatment Phase
Lung Cancer Advanced Stage Drug: Anlotinib,Erlotinib,IBI308,Pemetrexed,gemcitabine,carboplatin Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Anlotinib-based Combination as First-line Treatment in Advanced Non-small Cell Lung Cancer: a Single Center, Three Arms and Exploratory Study
Actual Study Start Date : July 20, 2018
Estimated Primary Completion Date : December 31, 2019
Estimated Study Completion Date : December 31, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
arm A
Anlotinib combined with erlotinib. Anlotinib will be given at a dose of 10mg once daily on days 1-14 of a 21-day cycle. Erlotinib will be given at a dose of 150mg once daily.
Drug: Anlotinib,Erlotinib,IBI308,Pemetrexed,gemcitabine,carboplatin
Patient harboring EGFR mutation will be enrolled into arm A. Patients without sensitive EGFR mutation will be assigned to either arm B or arm C based on patients' or treating physicians'choice

arm B
Anlotinib combined with chemotherapy. Anlotinib will be given at a dose of 12mg once daily on days 1-14 of a 21-day cycle. Pemetrexed (just for adenocarcinoma) will be given intravenously at a dose of 500mg per square meter of body surface area every 3 weeks; gemcitabine (just for squamous carcinoma) will be given intravenously at a dose of 1000mg per square meter of body surface area every 3 weeks; carboplatin will be given intravenously with a target area under the curve of 5 mg per milliliter per minute every 3 weeks.
Drug: Anlotinib,Erlotinib,IBI308,Pemetrexed,gemcitabine,carboplatin
Patient harboring EGFR mutation will be enrolled into arm A. Patients without sensitive EGFR mutation will be assigned to either arm B or arm C based on patients' or treating physicians'choice

arm C
Anlotinib combined with IBI308. Anlotinib will be given at a dose of 12mg once daily on days 1-14 of a 21-day cycle. IBI308 will be given intravenously at a dose of 200mg every 3 weeks.
Drug: Anlotinib,Erlotinib,IBI308,Pemetrexed,gemcitabine,carboplatin
Patient harboring EGFR mutation will be enrolled into arm A. Patients without sensitive EGFR mutation will be assigned to either arm B or arm C based on patients' or treating physicians'choice




Primary Outcome Measures :
  1. Safety will be assessed according to common terminology criteria for adverse events version 4.0 (CTC AE 4.0) [ Time Frame: from initiation of treatment to 90 days after the treatment finished ]
  2. ORR [ Time Frame: at the time of 8 weeks (2 cycles after treatment) ]
    Treatment response are defined as complete response (CR), partial response (PR), stable disease (SD) and progression disease (PD) according to Response Evaluation Criteria in Solid Tumor (RECISIT criteria, version 1.1). The percentage of patients who achieved CR and PR was defined as objective response rate (ORR)


Secondary Outcome Measures :
  1. DCR [ Time Frame: at the time of 8 weeks (2 cycles after treatment) ]
    Treatment response are defined as complete response (CR), partial response (PR), stable disease (SD) and progression disease (PD) according to Response Evaluation Criteria in Solid Tumor (RECISIT criteria, version 1.1) and the percentage of patients who achieved CR, PR and SD was defined as disease control rate (DCR).

  2. PFS [ Time Frame: From date of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 20 months ]
    PFS is defined as the time from the date of treatment to the first date of disease progression or death from any cause.

  3. OS [ Time Frame: From date of treatment until the date of death from any cause, assessed up to 50 months ]
    OS is calculated from diagnosis to death or last follow-up time.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients have voluntarily to join the study and give written informed consent for the study
  2. Histologically documented, unresectable, inoperable, locally advanced, recurrent or metastatic stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
  3. A cytologic diagnosis is acceptable (i.e., FNA or pleural fluid cytology)
  4. Mutation status including EGFR, ALK ROS are explicit;
  5. At least 1 unidimensionally measurable lesion meeting Response Evaluation Criteria in Solid Tumours (RECIST) criteria.
  6. Patients did not receive systemic anti-cancer therapy previously, including traditional Chinese medicine.
  7. Able to comply with study and follow-up procedures
  8. Age ≥ 18 years and ≤ 75, ECOG PS: 0~1, estimated survival duration more than 3 months;enough organ function;

8)Major organ function

  1. For regular test results(no blood transfusion within 14 days):

    1. Hemoglobin(HB)≥90g/L;
    2. Absolute neutrophils count(ANC)≥1.5×109/L;
    3. Blood platelets(PLT)≥80×109/L
  2. Biochemical tests results defined as follows:

    1. Total bilirubin(TBIL)≤1.5 times the upper limit of normal (ULN) ;
    2. Alanine aminotransferase(ALT)and aspartate aminotransgerase AST≤2.5ULN,liver metastases,if any,ALT和AST≤5ULN;
    3. Creatinine(Cr)≤1.5ULN or Creatinine Clearance rate (CCr)≥60 ml/min;
  3. Doppler ultrasound assessment:left ventricular ejection fraction (LVEF) ≥the lower limit of normal value(50%).

Exclusion Criteria:

  1. Small cell lung cancer(including patients with mixed small cell lung cancer and non-small cell lung cancer) or central squamous cell carcinoma with cavity
  2. Mutation status are unknown
  3. Previously (within 5 years) or presently suffering from other malignancies,
  4. Symptomatic or uncontrolled brain metastases
  5. Unstable systemic disease, including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, or myocardial infarction within 6 months or serious cardiac arrhythmia requiring medication
  6. History of other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the results of the study or render the patient at high risk from treatment complications
  7. Gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for intravenous (IV) alimentation, or prior surgical procedures affecting absorption
  8. Pregnancy or lactation
  9. Previously treated including treated with traditional Chinese medicine
  10. Patients who are allergic to any of the agent or any ingredient -

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03628521


Locations
Layout table for location information
China, Shanghai
Shanghai Chest Hospital Recruiting
Shanghai, Shanghai, China, 200030
Contact: Baohui Han, MD,PhD    +8618930858216    18930858216@163.com   
Sponsors and Collaborators
Shanghai Chest Hospital

Layout table for additonal information
Responsible Party: Baohui Han, professor, Shanghai Chest Hospital
ClinicalTrials.gov Identifier: NCT03628521     History of Changes
Other Study ID Numbers: ACTION
First Posted: August 14, 2018    Key Record Dates
Last Update Posted: August 14, 2018
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: The data used or analyzed during the current study are available from the principle investigator on reasonable request after 6 months of the project is finished.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Baohui Han, Shanghai Chest Hospital:
lung cancer
first-line
combination
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Gemcitabine
Carboplatin
Erlotinib Hydrochloride
Pemetrexed
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Protein Kinase Inhibitors
Folic Acid Antagonists
Nucleic Acid Synthesis Inhibitors